A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.
October 17, 2018
Premier Comments on ONC’s Request for Information on the EHR Reporting Program
Premier submitted comments in response to the Office of the National Coordinator for Health Information Technology (ONC) RFI on the EHR Reporting Program. The...
October 16, 2018
Premier Comments on the Medicare Shared Savings Program Proposed Rule
Premier submitted comments on the Centers for Medicare & Medicaid Services (CMS) Medicare Shared Savings Program (MSSP) Pathways to Success proposed rule, recommending changes to...
October 12, 2018
Premier Statement on NAM report: Procuring Interoperability
-By Blair Childs, Senior Vice President of Public Affairs, Premier Inc Members of Premier commend the National Academy of Medicine (NAM) for taking an...
October 09, 2018
Premier Statement on Bundled Payments for Care Improvement Advanced Model Participants
Premier commends the 1,299 entities that are joining the CMS Innovation Center’s Bundled Payments for Care Improvement (BPCI) Advanced Model.
October 04, 2018
Premier Statement on the SUPPORT Act
Premier and its members are proud to endorse the SUPPORT for Patients Communities Act passed by the Senate and sent to the President for signature.
October 02, 2018
Premier Statement on FDA Action to Address the Use of Citizen Petitions to Delay Market Competition of Generics and Biosimilars
Members of Premier applaud the Food and Drug Administration (FDA) for releasing revised draft guidance on the use of citizen petitions to delay the...
October 01, 2018
Premier Statement on ONC’s Blog Post Focused on Health Data and Interoperability
While it’s promising that many app developers appear to be coalescing around developing consumer apps using Fast Healthcare Interoperability Resources (FHIR®) and standard in health...
September 28, 2018
Premier Statement on the Importance of Enacting Reforms to 42 CFR Part 2
Premier and its members are extremely disappointed that the final compromise package (H.R. 6, the SUPPORT for Patients Communities Act) addressing the nation’s opioid epidemic...
September 26, 2018
Premier Statement on Congressional Action on Pharmacy Gag Clause Legislation (S. 2553 and S. 2554)
The Premier healthcare alliance and its members applaud the House of Representatives for advancing legislation that will help lower the cost of prescription drugs...
September 25, 2018
Premier Statement on Commitment to the CDC’s AMR Challenge
Premier is pleased to announce its commitment to the Centers for Disease Control and Prevention’s (CDC’s) Antibiotic Resistance (AMR) Challenge.
September 24, 2018
Premier Comments on CY19 Medicare Outpatient Payment Proposed Rule
Premier submitted comments on the Medicare hospital outpatient prospective payment system CY19 proposed rule, offering recommendations in regards to CMS’s proposed policies on 340B drug...
September 21, 2018
Premier Comments on FDA Biosimilars Action Plan
Premier offers recommendations in response to FDA’s Biosimilars Action Plan to encourage adoption of biosimilars and promote a competitive biosimilar marketplace.
September 14, 2018
Premier Statement on FDA’s Strategy to Combat Antibiotic Resistance
As a leader in researching, analyzing, developing and implementing measurable antimicrobial stewardship strategies, Premier is committed to reducing preventable harms caused by hospital-acquired infections and...
September 10, 2018
Premier Comments on CY19 Physician Fee Schedule/Quality Payment Program Proposed Rule
Premier submitted comments on CMS’s proposed policies related to off-campus provider based departments, E/M visits, Part B drug payment and the Quality Payment Program...
September 04, 2018
Premier Testifies During FDA Biological Products Marketplace Hearing
Premier testified during the Food and Drug Administration’s (FDA’s) public hearing to facilitate competition and innovation in the biological products marketplace on Sept. 4, 2018...
July 26, 2018
Biosimilars Competition Act Letter
Premier Inc. comment letter to Congressman Sarbanes and Congressman Johnson to support the Biosimilars Competition Act of 2018.
